Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Oncology/Hematology Market Research

Cancer Biologics Therapies Market Report 2021-2031

Price Length Publisher Published Date SKU
from $4,938 478 Pages Visiongain April, 2021 VSG16687411
Price from $4,938
Length 478 Pages
Publisher Visiongain
Published Date April, 2021
SKU VSG16687411

Cancer Biologics Therapies Market Report 2021-2031

Forecasts by Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), by Product (Monoclonal Antibodies, Cytokines, Cancer Growth Blockers, Vaccines, Blood Cell Growth Factors, and Others), by Indication (Breast Cancer, Cervical Cancer, Colon and Rectal Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Renal Cell Cancer, Melanoma), by Biologic Drugs (Bevacizumab, Trastuzumab, Trastuzumab Emtansine, Pertuzumab, Rituximab, Cetuximab, Panitumumab, Ramucirumab, Necitumumab, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Ipilimumab), by End-user (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cancer Biologics Companies AND COVID-19 Recovery Scenarios.

This report is intended to provide an in-depth analysis of the latest trends prevailing in the cancer biologics therapy market and its growth and development in the next decade. The changing demographics of the world population, increasing cancer prevalence, developing healthcare infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.

Cancer Biologics Therapy Market: Regional Landscape

Presence of well-established healthcare infrastructure and biopharmaceutical companies are expected to further strengthen North America cancer biologics therapy market in coming years. Increasing government initiatives to strengthen healthcare industry, rising prevalence of chronic diseases, followed by increasing healthcare expenditure in emerging economies are expected to drive Asia Pacific cancer biologics therapy market over the forecast period.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

What are the Market Driving Factors?

  • Rising Cancer Prevalence Worldwide
  • Increasing Ageing Population in Developed as well as Developing Economies
Key Challenges for Cancer Biologics Therapy Market
  • Shortage of Skilled Workforce in the Biopharmaceutical Industry
  • High Cost Associated with Biopharmaceutical Drug Manufacturing
What are the Market Opportunities?
  • Increasing R&D Spending of Biopharmaceutical Companies
  • Future Perspective in Oncology Industry
Why you Should buy this Report?

Apart from market estimation and forecast to 2031 the report covers below mentioned important factors to offer in-depth analysis of cancer biologics industry
  • SWOT Analysis
  • Porter’s Five Forces Model
  • Oncology Market Trends
  • Global Oncology Spending, 2016 – 2031
  • Disease Prevalence and Incidence in Europe by Country
  • EMA Approved Biologics in Oncology
  • Biosimilars and R&D Biologics in Development
What are the Leading Companies Operating in the Market?
  • AbbVie Inc
  • F.Hoffman La Roche
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Amgen
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories
  • GE Healthcare
  • Illumina
  • Qiagen N.V.
  • Biocept
  • Guardant Health
Market Segmentation and Scope

Cancer Biologics Therapy Market by Treatment
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Others
Cancer Biologics Therapy Market by Indication
  • Breast cancer
  • Cervical cancer
  • Colon and rectal cancer
  • Gastric cancer
  • Lung cancer
  • Ovarian cancer
  • Renal cell cancer
  • Melanoma
Cancer Biologics Therapy Market by Biologic Drug
  • Bevacizumab
  • Trastuzumab
  • Trastuzumab emtansine
  • Pertuzumab
  • Rituximab
  • Cetuximab
  • Panitumumab
  • Ramucirumab
  • Necitumumab
  • Pembrolizumab
  • Atezolizumab
  • Durvalumab
  • Nivolumab
  • Ipilimumab
Cancer Biologics Therapy Market by End User
  • Hospitals
  • Specialty Clinics
  • Cancer and Radiation Therapy Centers
Cancer Biologics Therapy Market by Product
  • Monoclonal Antibodies
  • Cytokines
  • Cancer Growth Blockers
  • Vaccines
  • Blood Cell Growth Factors
  • Others
Cancer Biologics Therapy Market by Region
  • North America Cancer Biologics Therapy Market
  • U.S. Cancer Biologics Therapy Market
  • Canada Cancer Biologics Therapy Market
  • Europe Cancer Biologics Therapy Market
  • UK Cancer Biologics Therapy Market
  • Germany Cancer Biologics Therapy Market
  • France Cancer Biologics Therapy Market
  • Italy Cancer Biologics Therapy Market
  • Spain Cancer Biologics Therapy Market
  • Portugal Cancer Biologics Therapy Market
  • Poland Cancer Biologics Therapy Market
  • Hungary Cancer Biologics Therapy Market
  • Czech Republic Cancer Biologics Therapy Market
  • Slovakia Cancer Biologics Therapy Market
  • Slovenia Cancer Biologics Therapy Market
  • Romania Cancer Biologics Therapy Market
  • Bulgaria Cancer Biologics Therapy Market
  • Croatia Cancer Biologics Therapy Market
  • Baltic States Cancer Biologics Therapy Market
  • Serbia Cancer Biologics Therapy Market
  • Asia Pacific Cancer Biologics Therapy Market
  • China Cancer Biologics Therapy Market
  • Japan Cancer Biologics Therapy Market
  • India Cancer Biologics Therapy Market
  • Australia Cancer Biologics Therapy Market
  • South Korea Cancer Biologics Therapy Market
  • Rest of Asia Pacific Cancer Biologics Therapy Market
  • Latin America Cancer Biologics Therapy Market
  • Brazil Cancer Biologics Therapy Market
  • Mexico Cancer Biologics Therapy Market
  • Argentina Cancer Biologics Therapy Market
  • Rest of Latin America Cancer Biologics Therapy Market
  • Middle East & Africa Cancer Biologics Therapy Market
  • South Africa Cancer Biologics Therapy Market
  • GCC Cancer Biologics Therapy Market
  • Rest of Middle East & Africa Cancer Biologics Therapy Market
Need industry data? Please contact us today.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Cancer Biologics Therapies Market and leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1.
2. Report Overview
1.1. Global Cancer Biologics Therapy Market Overview
1.2. Why You Should Read This Report
1.3. How This Report Delivers
1.4. Key Questions Answered by This Analytical Report
1.5. Who Is This Report For?
1.6. Methodology
1.6.1. Primary Research
1.6.2. Secondary Research
1.6.3. Market Evaluation & Forecasting Methodology
1.7. Frequently Asked Questions (FAQ)
1.8. Associated Visiongain Reports
1.9. About Visiongain
2. Introduction to the Cancer Biologics Therapy Market
2.1. Cancer Biologics Therapy Market Definition
2.2. Treatments used in Cancer Biologics Therapy Industry
2.2.1. Chemotherapy
2.2.2. Targeted Therapy
2.2.2.1. Monoclonal Antibodies
2.2.2.2. Small-Molecule Drugs
2.2.3. Immunotherapy
2.2.4. Hormonal Therapy
2.3. Cancer Biologics Therapy Industry by Indication
2.3.1. Breast Cancer
2.3.2. Cervical Cancer
2.3.3. Colon and Rectal Cancer
2.3.4. Gastric Cancer
2.3.5. Lung Cancer
2.3.6. Ovarian Cancer
2.3.7. Renal Cell Cancer
2.3.8. Melanoma
3. Cancer Biologics Therapy Market Overview
3.1. Global Oncology Spending Market Size, Market Analysis and Forecast, 2016-2031
3.2. Global and Regional Cancer Biologics Therapy Market, 2016-2031
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Cancer Prevalence Worldwide
3.3.1.2. Increasing Ageing Population in Developed as well as Developing Economies
3.3.2. Market Restraints/Challenges
3.3.2.1. Shortage of Skilled Workforce in the Biopharmaceutical Industry
3.3.2.2. High Cost Associated with Biopharmaceutical Drug Manufacturing
3.3.3. Opportunities
3.3.3.1. Increasing R&D Spending of Biopharmaceutical Companies
3.3.3.2. Future Perspective in Oncology Industry
3.4. Cancer Biologics Therapy Market: SWOT Analysis
3.5. Cancer Biologics Therapy Market: Porter’s Five Forces Model
3.5.1. Bargaining Power of Buyers
3.5.2. Bargaining Power of Suppliers
3.5.3. Threats of New Entrants
3.5.4. Threats of Substitutes
3.5.5. Competitive Rivalry
3.6. European Oncology Market Trends
3.7. Disease Prevalence and Incidence in Europe
3.7.1. Germany Cancer Incidence and Mortality
3.7.2. UK Cancer Incidence and Mortality
3.7.3. France Cancer Incidence and Mortality
3.7.4. Italy Cancer Incidence and Mortality
3.7.5. Spain Cancer Incidence and Mortality
3.7.6. Portugal Cancer Incidence and Mortality
3.7.7. Poland Cancer Incidence and Mortality
3.7.8. Hungary Cancer Incidence and Mortality
3.7.9. Czech Republic Cancer Incidence and Mortality
3.7.10. Slovakia Cancer Incidence and Mortality
3.7.11. Slovenia Cancer Incidence and Mortality
3.7.12. Romania Cancer Incidence and Mortality
3.7.13. Bulgaria Cancer Incidence and Mortality
3.7.14. Croatia Cancer Incidence and Mortality
3.7.15. Serbia Cancer Incidence and Mortality
3.7.16. Estonia Cancer Incidence and Mortality
3.7.17. Latvia Cancer Incidence and Mortality
3.7.18. Lithuania Cancer Incidence and Mortality
3.8. Prescription Distribution of Bevacizumab and Trastuzumab
3.8.1. Prescription Distribution of Bevacizumab
3.8.1.1. Metastatic Colorectal Cancer
3.8.1.2. First-Line Non-Squamous Non–Small Cell Lung Cancer
3.8.1.3. Recurrent Glioblastoma
3.8.1.4. Metastatic Renal Cell Carcinoma
3.8.1.5. Persistent, Recurrent, Or Metastatic Cervical Cancer
3.8.1.6. Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
3.8.1.7. Hepatocellular Carcinoma
3.8.2. Prescription Distribution of Trastuzumab
3.8.2.1. Adjuvant Breast Cancer
3.8.2.2. Metastatic Breast Cancer
3.8.2.3. Metastatic Gastric Cancer
3.9. EMA Approval, Loss of Exclusivity and Introduction of Biosimilars Impact Analysis
3.10. Therapeutic Schemes of Bevacizumab and Trastuzumab
3.11. Patient drop-out rate
3.12. Oncologist Perceptions on Biosimilars
3.13. Barriers to Biologic Treatments and Expected Impact of Cheaper Options on the Market
3.14. Biosimilars and R&D Biologics in Development
3.14.1. Current Bevacizumab Biosimilars
3.14.2. Current Trastuzumab Biosimilars
3.14.3. Melanoma Indications
4. Global Cancer Biologics Therapy Market Analysis and Forecast 2021-2031, by Treatment Type
4.1. Chemotherapy Market Size
4.1.1. Side Effects of Chemotherapy
4.1.2. Cancer Biologics Therapy Market Outlook for Chemotherapy: Recovery Scenarios (V, U, L, W)
4.2. Targeted Therapy Market Size
4.2.1. Examples of Targeted Therapies
4.2.2. Targeted Therapies Approved for Specific Types of Cancer
4.2.3. Cancer Biologics Therapy Market Outlook for Targeted Therapy: Recovery Scenarios (V, U, L, W)
4.2.4. Tyrosine kinase inhibitors (small molecules) / mTOR, BRAF, etc. receptor targeted agents
4.2.5. Monoclonal antibodies / mAbs (VEGF, HER, DP1, etc. receptor targeted agents)
4.2.6. Antibody-drug conjugates – with mAbs or with a small molecule
4.3. Immunotherapy Market Size
4.3.1. What Does Immunotherapy Treat?
4.3.2. Types of Immunotherapy
4.3.3. Cancer Biologics Therapy Market Outlook for Immunotherapy: Recovery Scenarios (V, U, L, W)
4.4. Hormonal Therapy Market Size
4.4.1. Hormone Therapy for Breast Cancer
4.4.2. Hormone Therapy Drugs for Breast Cancer
4.4.3. Breast Cancer and Tamoxifen
4.4.4. Cancer Biologics Therapy Market Outlook for Hormonal Therapy: Recovery Scenarios (V, U, L, W)
4.5. Other Treatments Market Size
4.5.1. Are there Vaccines that Prevent Cancer?
4.5.2. Cancer Biologics Therapy Market Outlook for Other Treatments: Recovery Scenarios (V, U, L, W)
5. Global Cancer Biologics Therapy Market Analysis and Forecast 2021-2031, by Indication
5.1. Breast Cancer Market Size
5.1.1. Node Preservation Reduces Lymphedema Cases
5.1.2. Genomic Testing Minimizes Chemotherapy Exposure
5.1.3. Oral Option for Targeted Therapy
5.1.4. Breast Cancer Statistics, 2020
5.1.5. Cancer Biologics Therapy Market Outlook for Breast Cancer: Recovery Scenarios (V, U, L, W)
5.2. Cervical Cancer Market Size
5.2.1. Cancer Biologics Therapy Market Outlook for Cervical Cancer: Recovery Scenarios (V, U, L, W)
5.3. Colon and Rectal Cancer Market Size
5.3.1. Drugs Approved for Colon Cancer
5.3.2. Drugs Combinations Used in Colon Cancer
5.3.3. Drugs Approved for Rectal Cancer
5.3.4. Drugs Combinations Used in Rectal Cancer
5.3.5. Cancer Biologics Therapy Market Outlook for Colon and Rectal Cancer: Recovery Scenarios (V, U, L, W)
5.4. Gastric Cancer Market Size
5.4.1. Drugs Approved for Gastric Cancer
5.4.2. Drugs Combinations Used in Gastric Cancer
5.4.3. Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors
5.4.4. Cancer Biologics Therapy Market Outlook for Gastric Cancer: Recovery Scenarios (V, U, L, W)
5.5. Lung Cancer Market Size
5.5.1. Drugs Approved for Non-Small Cell Lung Cancer
5.5.2. Drug Combinations Used to Treat Non-Small Cell Lung Cancer
5.5.3. Drugs Approved for Small Cell Lung Cancer
5.5.4. Cancer Biologics Therapy Market Outlook for Lung Cancer: Recovery Scenarios (V, U, L, W)
5.6. Ovarian Cancer Market Size
5.6.1. Available Treatments for Ovarian Cancer
5.6.2. What New Treatment Options are Under Development?
5.6.3. Cancer Biologics Therapy Market Outlook for Ovarian Cancer: Recovery Scenarios (V, U, L, W)
5.7. Renal Cell Cancer Market Size
5.7.1. Cancer Biologics Therapy Market Outlook for Renal Cell Cancer: Recovery Scenarios (V, U, L, W)
5.8. Melanoma Market Size
5.8.1. Drugs Approved for Melanoma
5.8.2. Cancer Biologics Therapy Market Outlook for Melanoma: Recovery Scenarios (V, U, L, W)
5.9. Other Indications Market Size
5.9.1. Cancer Biologics Therapy Market Outlook for Other Indications: Recovery Scenarios (V, U, L, W)
6. Global Cancer Biologics Therapy Market Analysis and Forecast 2021-2031, by Biologic Drugs
6.1. Bevacizumab Market Size
6.1.1. Bevacizumab Similar Biologic Launched in India
6.1.2. Cancer Biologics Therapy Market Outlook for Bevacizumab: Recovery Scenarios (V, U, L, W)
6.2. Trastuzumab Market Size
6.2.1. Cancer Biologics Therapy Market Outlook for Trastuzumab: Recovery Scenarios (V, U, L, W)
6.3. Trastuzumab emtansine Market Size
6.3.1. Cancer Biologics Therapy Market Outlook for Trastuzumab emtansine: Recovery Scenarios (V, U, L, W)
6.4. Pertuzumab Market Size
6.4.1. FDA Accepted Roche’s Biologics License Application
6.4.2. Cancer Biologics Therapy Market Outlook for Pertuzumab: Recovery Scenarios (V, U, L, W)
6.5. Rituximab Market Size
6.5.1. Cancer Biologics Therapy Market Outlook for Rituximab: Recovery Scenarios (V, U, L, W)
6.6. Cetuximab Market Size
6.6.1. Cancer Biologics Therapy Market Outlook for Cetuximab: Recovery Scenarios (V, U, L, W)
6.7. Panitumumab Market Size
6.7.1. Cancer Biologics Therapy Market Outlook for Panitumumab: Recovery Scenarios (V, U, L, W)
6.8. Ramucirumab Market Size
6.8.1. Cancer Biologics Therapy Market Outlook for Ramucirumab: Recovery Scenarios (V, U, L, W)
6.9. Necitumumab Market Size
6.9.1. Role of Necitumumab in the Treatment of Non–Small Cell Lung Cancer (NSCLC)?
6.9.2. Cancer Biologics Therapy Market Outlook for Necitumumab: Recovery Scenarios (V, U, L, W)
6.10. Pembrolizumab Market Size
6.10.1. What Pembrolizumab Is Used For:
6.10.2. Cancer Biologics Therapy Market Outlook for Pembrolizumab: Recovery Scenarios (V, U, L, W)
6.11. Atezolizumab Market Size
6.11.1. Atezolizumab Drug Used in below Indications
6.11.2. Cancer Biologics Therapy Market Outlook for Atezolizumab: Recovery Scenarios (V, U, L, W)
6.12. Durvalumab Market Size
6.12.1. FDA Approved Durvalumab for Extensive-Stage Small Cell Lung Cancer
6.12.2. Cancer Biologics Therapy Market Outlook for Durvalumab: Recovery Scenarios (V, U, L, W)
6.13. Nivolumab Market Size
6.13.1. FDA to Review Additional GI Cancer Indications for Nivolumab
6.13.2. Cancer Biologics Therapy Market Outlook for Nivolumab: Recovery Scenarios (V, U, L, W)
6.14. Ipilimumab Market Size
6.14.1. Cancer Biologics Therapy Market Outlook for Ipilimumab: Recovery Scenarios (V, U, L, W)
7. Global Cancer Biologics Therapy Market Analysis and Forecast 2021-2031, by Product
7.1. Monoclonal Antibodies Market Size
7.1.1. Cancer Biologics Therapy Market Outlook for Monoclonal Antibodies: Recovery Scenarios (V, U, L, W)
7.2. Cytokines Market Size
7.2.1. Cancer Biologics Therapy Market Outlook for Cytokines: Recovery Scenarios (V, U, L, W)
7.3. Cancer Growth Blockers Market Size
7.3.1. Types of Cancer Growth Blockers
7.3.2. Possible Side Effects of Cancer Growth Blockers
7.3.3. Cancer Biologics Therapy Market Outlook for Cancer Growth Blockers: Recovery Scenarios (V, U, L, W)
7.4. Vaccines Market Size
7.4.1. Cancer Biologics Therapy Market Outlook for Vaccines: Recovery Scenarios (V, U, L, W)
7.5. Blood Cell Growth Factors Market Size
7.5.1. Cancer Biologics Therapy Market Outlook for Blood Cell Growth Factors: Recovery Scenarios (V, U, L, W)
7.6. Others Market Size
7.6.1. Cancer Biologics Therapy Market Outlook for Others: Recovery Scenarios (V, U, L, W)
8. Global Cancer Biologics Therapy Market Analysis and Forecast 2021-2031, by End User
8.1. Hospitals Market Size
8.1.1. Cancer Biologics Therapy Market Outlook for Hospitals: Recovery Scenarios (V, U, L, W)
8.2. Specialty Clinics Market Size
8.2.1. Cancer Biologics Therapy Market Outlook for Specialty Clinics: Recovery Scenarios (V, U, L, W)
8.3. Cancer and Radiation Therapy Centers Market Size
8.3.1. How is the Cancer Research Institute Involved in the Development of Immunotherapy?
8.3.2. Cancer Biologics Therapy Market Outlook for Cancer and Radiation Therapy Centers: Recovery Scenarios (V, U, L, W)
9. North America Cancer Biologics Therapy Market Analysis and Forecast, 2021-2031
9.1. North America Cancer Biologics Therapy Market Size
9.1.1. North America Cancer Biologics Therapy Market Outlook: Recovery Scenarios (V, U, L, W)
9.2. U.S. Cancer Biologics Therapy Market Size
9.3. Canada Cancer Biologics Therapy Market Size
10. Europe Cancer Biologics Therapy Market Analysis and Forecast, 2021-2031
10.1. Europe Cancer Biologics Therapy Market Size
10.1.1. Europe Cancer Biologics Therapy Market Outlook: Recovery Scenarios (V, U, L, W)
10.2. UK Cancer Biologics Therapy Market Size
10.3. Germany Cancer Biologics Therapy Market Size
10.4. France Cancer Biologics Therapy Market Size
10.5. Italy Cancer Biologics Therapy Market Size
10.6. Spain Cancer Biologics Therapy Market Size
10.7. Portugal Cancer Biologics Therapy Market Size
10.8. Poland Cancer Biologics Therapy Market Size
10.9. Hungary Cancer Biologics Therapy Market Size
10.10. Czech Republic Cancer Biologics Therapy Market Size
10.11. Slovakia Cancer Biologics Therapy Market Size
10.12. Slovenia Cancer Biologics Therapy Market Size
10.13. Romania Cancer Biologics Therapy Market Size
10.14. Bulgaria Cancer Biologics Therapy Market Size
10.15. Croatia Cancer Biologics Therapy Market Size
10.16. Baltic States Cancer Biologics Therapy Market Size
10.17. Serbia Cancer Biologics Therapy Market Size
10.18. Rest of Europe Cancer Biologics Therapy Market Size
11. Asia Pacific Cancer Biologics Therapy Market Analysis and Forecast, 2021-2031
11.1. Asia Pacific Cancer Biologics Therapy Market Size
11.1.1. Asia Pacific Cancer Biologics Therapy Market Outlook: Recovery Scenarios (V, U, L, W)
11.2. China Cancer Biologics Therapy Market Size
11.3. India Cancer Biologics Therapy Market Size
11.4. Japan Cancer Biologics Therapy Market Size
11.5. South Korea Cancer Biologics Therapy Market Size
11.6. Australia Cancer Biologics Therapy Market Size
11.7. Rest of Asia Pacific Cancer Biologics Therapy Market Size
12. Latin America Cancer Biologics Therapy Market Analysis and Forecast, 2021-2031
12.1. Latin America Cancer Biologics Therapy Market Size
12.1.1. Latin America Cancer Biologics Therapy Market Outlook: Recovery Scenarios (V, U, L, W)
12.2. Brazil Cancer Biologics Therapy Market Size
12.3. Mexico Cancer Biologics Therapy Market Size
12.4. Argentina Cancer Biologics Therapy Market Size
12.5. Rest of Latin America Cancer Biologics Therapy Market Size
13. Middle East & Africa Cancer Biologics Therapy Market Analysis and Forecast, 2021-2031
13.1. Middle East & Africa Cancer Biologics Therapy Market Size
13.1.1. Middle East & Africa Cancer Biologics Therapy Market Outlook: Recovery Scenarios (V, U, L, W)
13.2. South Africa Cancer Biologics Therapy Market Size
13.3. GCC Cancer Biologics Therapy Market Size
13.4. Rest of Middle East & Africa Cancer Biologics Therapy Market Size
14. Company Profiles
14.1. AbbVie Inc.
14.1.1. AbbVie Inc. Snapshot
14.1.2. Company Overview
14.1.3. Product Offerings
14.1.4. AbbVie Inc.: Recent Initiatives, 2017 – 2020
14.1.5. Financial Performance (2015 – 2019)
14.1.5.1. Net Revenue (2015 – 2019)
14.1.5.2. Gross Profit (2015 – 2019)
14.1.5.3. Geographical Revenue, 2019
14.2. F.Hoffman La Roche
14.2.1. F.Hoffman La Roche Snapshot
14.2.2. Company Overview
14.2.3. Product Offerings
14.2.4. F.Hoffman La Roche: Recent Initiatives, 2017 – 2020
14.2.5. Financial Performance (2015 – 2019)
14.2.5.1. Net Revenue (2015 – 2019)
14.2.5.2. Gross Profit (2015 – 2019)
14.2.5.3. Geographical Revenue, 2019
14.3. GlaxoSmithKline
14.3.1. GlaxoSmithKline Snapshot
14.3.2. Company Overview
14.3.3. Product Offerings
14.3.4. GlaxoSmithKline: Recent Initiatives, 2017 – 2020
14.3.5. Financial Performance (2015 – 2019)
14.3.5.1. Net Revenue (2015 – 2019)
14.3.5.2. Gross Profit (2015 – 2019)
14.3.5.3. Geographical Revenue, 2019
14.4. Eli Lilly and Company
14.4.1. Eli Lilly and Company Snapshot
14.4.2. Company Overview
14.4.3. Product Offerings
14.4.4. Eli Lilly and Company: Recent Initiatives, 2017 – 2020
14.4.5. Financial Performance (2015 – 2019)
14.4.5.1. Net Revenue (2015 – 2019)
14.4.5.2. Gross Profit (2015 – 2019)
14.4.5.3. Geographical Revenue, 2019
14.5. Amgen
14.5.1. Amgen Snapshot
14.5.2. Company Overview
14.5.3. Product Offerings
14.5.4. Amgen: Recent Initiatives, 2017 – 2020
14.5.5. Financial Performance (2015 – 2019)
14.5.5.1. Net Revenue (2015 – 2019)
14.5.5.2. Gross Profit (2015 – 2019)
14.5.5.3. Geographical Revenue, 2019
14.6. Johnson & Johnson
14.6.1. Johnson & Johnson Snapshot
14.6.2. Company Overview
14.6.3. Product Offerings
14.6.4. Johnson & Johnson: Recent Initiatives, 2017 – 2020
14.6.5. Financial Performance (2015 – 2019)
14.6.5.1. Net Revenue (2015 – 2019)
14.6.5.2. Gross Profit (2015 – 2019)
14.6.5.3. Geographical Revenue, 2019
14.7. Merck & Co.
14.7.1. Merck & Co. Snapshot
14.7.2. Company Overview
14.7.3. Product Offerings
14.7.4. Merck & Co.: Recent Initiatives, 2017 – 2020
14.7.5. Financial Performance (2015 – 2019)
14.7.5.1. Net Revenue (2015 – 2019)
14.7.5.2. Gross Profit (2015 – 2019)
14.7.5.3. Geographical Revenue, 2019
14.8. Pfizer
14.8.1. Pfizer Snapshot
14.8.2. Company Overview
14.8.3. Product Offerings
14.8.4. Pfizer: Recent Initiatives, 2017 – 2020
14.8.5. Financial Performance (2015 – 2019)
14.8.5.1. Net Revenue (2015 – 2019)
14.8.5.2. Gross Profit (2015 – 2019)
14.8.5.3. Geographical Revenue, 2019
14.9. Agilent Technologies, Inc.
14.9.1. Company Overview
14.9.2. Product Benchmarking
14.9.3. Agilent Technologies, Inc.: Recent Initiatives
14.9.4. Financial Performance (2016 – 2019)
14.10. Bio-Rad Laboratories
14.10.1. Company Overview
14.10.2. Product Benchmarking
14.10.3. Bio-Rad Laboratories: Selected Recent Contracts / Projects / Programmes / News/ Mergers & Acquisitions
14.10.4. Financials
14.11. GE Healthcare
14.11.1. Company Overview
14.11.2. Product Benchmarking
14.11.3. GE Healthcare: Selected Recent Contracts / Projects / Programmes / News/ Mergers & Acquisitions
14.11.4. Financials
14.12. Illumina
14.12.1. Company Overview
14.12.2. Product Benchmarking
14.12.3. Illumina: Selected Recent Contracts / Projects / Programmes / News/ Mergers & Acquisitions
14.12.4. Financials
14.13. Qiagen N.V.
14.13.1. Company Overview
14.13.2. Product Benchmarking
14.13.3. Qiagen N.V.: Selected Recent Contracts / Projects / Programmes / News/ Mergers & Acquisitions
14.13.4. Financials
14.14. Biocept
14.14.1. Biocept Snapshot
14.14.2. Company Overview
14.14.3. Product Offerings
14.14.4. Biocept: Recent Initiatives, 2017 – 2020
14.14.5. Financial Performance (2015 – 2019)
14.15. Guardant Health
14.15.1. Guardant Health Snapshot
14.15.2. Company Overview
14.15.3. Product Offerings
14.15.4. Guardant Health: Recent Initiatives, 2017 – 2020
14.15.5. Financial Performance (2015 – 2019)
15. Conclusion
15.1. Concluding Remarks
15.2. Recommendations
List of Figures
Figure 1 Cancer Biologics Therapy: Market Segmentation and Scope
Figure 2 Global Oncology Spending Market Value Forecast, 2016 – 2031 (USD Billion)
Figure 3 Global Oncology Spending Market Share by Region, 2020 (%)
Figure 4 Cancer Biologics Therapy Market Share by Region, 2021, 2026, 2031 (%)
Figure 5 Worldwide Cancer Death by Age, 2019 (%)
Figure 6 Share of population with Cancer, 2019 (%)
Figure 7 Ageing Population Estimates 2010 - 2050
Figure 8 Research & Development Spending as a Percent of Revenue by Biopharmaceutical Companies, 2019 (%)
Figure 9 Cancer Biologics Therapy Industry: Porter’s Five Forces Model
Figure 10 Germany: Estimated Incidence by Cancer, 2020 (%)
Figure 11 Germany: Estimated Mortality by Cancer, 2020 (%)
Figure 12 UK: Estimated Incidence by Cancer, 2020 (%)
Figure 13 UK: Estimated Mortality by Cancer, 2020 (%)
Figure 14 France: Estimated Incidence by Cancer, 2020 (%)
Figure 15 France: Estimated Mortality by Cancer, 2020 (%)
Figure 16 Italy: Estimated Incidence by Cancer, 2020 (%)
Figure 17 Italy: Estimated Mortality by Cancer, 2020 (%)
Figure 18 Spain: Estimated Incidence by Cancer, 2020 (%)
Figure 19 Spain: Estimated Mortality by Cancer, 2020 (%)
Figure 20 Portugal: Estimated Incidence by Cancer, 2020 (%)
Figure 21 Portugal: Estimated Mortality by Cancer, 2020 (%)
Figure 22 Poland: Estimated Incidence by Cancer, 2020 (%)
Figure 23 Poland: Estimated Mortality by Cancer, 2020 (%)
Figure 24 Hungary: Estimated Incidence by Cancer, 2020 (%)
Figure 25 Hungary: Estimated Mortality by Cancer, 2020 (%)
Figure 26 Czech Republic: Estimated Incidence by Cancer, 2020 (%)
Figure 27 Czech Republic: Estimated Mortality by Cancer, 2020 (%)
Figure 28 Slovakia: Estimated Incidence by Cancer, 2020 (%)
Figure 29 Slovakia: Estimated Mortality by Cancer, 2020 (%)
Figure 30 Slovenia: Estimated Incidence by Cancer, 2020 (%)
Figure 31 Slovenia: Estimated Mortality by Cancer, 2020 (%)
Figure 32 Romania: Estimated Incidence by Cancer, 2020 (%)
Figure 33 Romania: Estimated Mortality by Cancer, 2020 (%)
Figure 34 Bulgaria: Estimated Incidence by Cancer, 2020 (%)
Figure 35 Bulgaria: Estimated Mortality by Cancer, 2020 (%)
Figure 36 Croatia: Estimated Incidence by Cancer, 2020 (%)
Figure 37 Croatia: Estimated Mortality by Cancer, 2020 (%)
Figure 38 Serbia: Estimated Incidence by Cancer, 2020 (%)
Figure 39 Serbia: Estimated Mortality by Cancer, 2020 (%)
Figure 40 Estonia: Estimated Incidence by Cancer, 2020 (%)
Figure 41 Estonia: Estimated Mortality by Cancer, 2020 (%)
Figure 42 Latvia: Estimated Incidence by Cancer, 2020 (%)
Figure 43 Latvia: Estimated Mortality by Cancer, 2020 (%)
Figure 44 Lithuania: Estimated Incidence by Cancer, 2020 (%)
Figure 45 Lithuania: Estimated Mortality by Cancer, 2020 (%)
Figure 46 Cancer Biologics Therapy for Chemotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %)
Figure 47 Cancer Biologics Therapy for Chemotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): V Shaped Recovery
Figure 48 Cancer Biologics Therapy for Chemotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): U Shaped Recovery
Figure 49 Cancer Biologics Therapy for Chemotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): L Shaped Recovery
Figure 50 Cancer Biologics Therapy for Chemotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): W Shaped Recovery
Figure 51 Cancer Biologics Therapy for Targeted Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %)
Figure 52 Cancer Biologics Therapy for Targeted Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): V Shaped Recovery
Figure 53 Cancer Biologics Therapy for Targeted Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): U Shaped Recovery
Figure 54 Cancer Biologics Therapy for Targeted Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): L Shaped Recovery
Figure 55 Cancer Biologics Therapy for Targeted Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): W Shaped Recovery
Figure 56 Cancer Biologics Therapy for Immunotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %)
Figure 57 Cancer Biologics Therapy for Immunotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): V Shaped Recovery
Figure 58 Cancer Biologics Therapy for Immunotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): U Shaped Recovery
Figure 59 Cancer Biologics Therapy for Immunotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): L Shaped Recovery
Figure 60 Cancer Biologics Therapy for Immunotherapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): W Shaped Recovery
Figure 61 Cancer Biologics Therapy for Hormonal Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %)
Figure 62 Cancer Biologics Therapy for Hormonal Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): V Shaped Recovery
Figure 63 Cancer Biologics Therapy for Hormonal Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): U Shaped Recovery
Figure 64 Cancer Biologics Therapy for Hormonal Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): L Shaped Recovery
Figure 65 Cancer Biologics Therapy for Hormonal Therapy Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): W Shaped Recovery
Figure 66 Cancer Biologics Therapy for Other Treatments Market Value Forecast, 2021 – 2031 (USD Billion, AGR %)
Figure 67 Cancer Biologics Therapy for Other Treatments Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): V Shaped Recovery
Figure 68 Cancer Biologics Therapy for Other Treatments Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): U Shaped Recovery
Figure 69 Cancer Biologics Therapy for Other Treatments Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): L Shaped Recovery
Figure 70 Cancer Biologics Therapy for Other Treatments Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): W Shaped Recovery
Figure 71 Cancer Biologics Therapy for Breast Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %)
Figure 72 Cancer Biologics Therapy for Breast Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): V Shaped Recovery
Figure 73 Cancer Biologics Therapy for Breast Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): U Shaped Recovery
Figure 74 Cancer Biologics Therapy for Breast Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): L Shaped Recovery
Figure 75 Cancer Biologics Therapy for Breast Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): W Shaped Recovery
Figure 76 Cancer Biologics Therapy for Cervical Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %)
Figure 77 Cancer Biologics Therapy for Cervical Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): V Shaped Recovery
Figure 78 Cancer Biologics Therapy for Cervical Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): U Shaped Recovery
Figure 79 Cancer Biologics Therapy for Cervical Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): L Shaped Recovery
Figure 80 Cancer Biologics Therapy for Cervical Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): W Shaped Recovery
Figure 81 Cancer Biologics Therapy for Colon and Rectal Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %)
Figure 82 Cancer Biologics Therapy for Colon and Rectal Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): V Shaped Recovery
Figure 83 Cancer Biologics Therapy for Colon and Rectal Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): U Shaped Recovery
Figure 84 Cancer Biologics Therapy for Colon and Rectal Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): L Shaped Recovery
Figure 85 Cancer Biologics Therapy for Colon and Rectal Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): W Shaped Recovery
Figure 86 Cancer Biologics Therapy for Gastric Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %)
Figure 87 Cancer Biologics Therapy for Gastric Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): V Shaped Recovery
Figure 88 Cancer Biologics Therapy for Gastric Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): U Shaped Recovery
Figure 89 Cancer Biologics Therapy for Gastric Cancer Market Value Forecast, 2021 – 2031 (USD Billion, AGR %): L Shaped Recovery

$5,625
$8,688
$4,938
$6,875

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings